Top of this page
Skip navigation, go straight to the content
Scroll down to discover UCB
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
![CIMZIA[®] is the First and Only Biologic Approved in Europe with the Option for a Reduced Maintenance Dose for Patients Across the Full Axial Spondyloarthritis Spectrum](/_up/ucb_com_presscenter/images/presscenter_teaser_17.jpg?300)
Twitter Feed
-
UCB enters into collaboration with @Roche to develop antibody treatment for people living with #Alzheimers.
— UCB News (@ucb_news) 29.07.2020 -
Today's Phase 3b data announcement is the latest readout from UCB's robust #psoriasis clinical development program https://t.co/zCiDOBSlno
— UCB News (@ucb_news) 29.07.2020 -
Want to know more about UCB’s Community Health Fund mission and the first call for projects? Listen to Xavier Hormaechea, Secretary General of the UCB Community Health Fund
— UCB News (@ucb_news) 29.07.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
